Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 221

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

Open access
Pfeiler, Georg, Königsberg, Robert, Fesl, Christian, Mlineritsch, Brigitte, Stoeger, Herbert, Singer, Christian F., Pöstlberger, Sabine, Steger, Guenther G., Seifert, Michael, Dubsky, Peter, Taucher, Susanne, Samonigg, Hellmut, Bjelic-Radisic, Vesna, Greil, Richard, Marth, Christian, Gnant, Michael · 2011 · Journal of Clinical Oncology

Abstract

Purpose: Aromatase inhibitors are effective as endocrine treatment for patients with hormone receptor–positive breast cancer. According to the hypothesis that overweight patients have higher levels of aromatase enzyme availability, we investigated the influence of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in premenopausal patients in a retrospective analysis of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 trial. Patients and Methods: ABCSG-12 examined the efficacy of ovarian suppression using goserelin (3.6 mg subcutaneously every 28 days) in combination with anastrozole or tamoxifen with or without zoledronic acid (4 mg intravenously every 6 months) in premenopausal women with endocrine-responsive breast cancer. BMI was calculated using the prospectively collected data on patients' height and weight at study entry. BMI categories have been differentiated according to the WHO definition. Results: Overweight patients treated with anastrozole had a 60% increase in the risk of disease recurrence (hazard ratio [HR], 1.60; 95% CI, 1.06 to 2.41; P = .02) and more than a doubling in the risk of death (HR, 2.14; 95% CI, 1.17 to 3.92; P = .01) compared with normal weight patients treated with anastrozole. In the overweight group, patients treated with anastrozole had a nearly 50% increase in the risk of disease recurrence (HR, 1.49; 95% CI, 0.93 to 2.38; P = .08) and a three-fold increase in the risk of death (HR, 3.03; 95% CI, 1.35 to 6.82; P = .004) compared with patients treated with tamoxifen. Conclusion: BMI significantly impacts on the efficacy of anastrozole plus goserelin in premenopausal patients with breast cancer, probably through influencing aromatase availability and/or ovarian suppression by goserelin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.33.2585

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 221

Metadata

Authors
Pfeiler, G., Königsberg, R., Fesl, C., Mlineritsch, B., Stoeger, H., Singer, C. F., Pöstlberger, S., Steger, G. G., Seifert, M., Dubsky, P., Taucher, S., Samonigg, H., Bjelic-Radisic, V., Greil, R., Marth, C., & Gnant, M.
Venue
Journal of Clinical Oncology
Published
2011-07-01
Volume
29
Issue
19
Pages
2653-2659
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2116902655
Cited by
221
References
4
FWCI
9.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. https://app.cochat.ai/papers/10.1200/jco.2010.33.2585
The paper
Pfeiler, G., Königsberg, R., Fesl, C., Mlineritsch, B., Stoeger, H., Singer, C. F., Pöstlberger, S., Steger, G. G., Seifert, M., Dubsky, P., Taucher, S., Samonigg, H., Bjelic-Radisic, V., Greil, R., Marth, C., & Gnant, M. (2011). Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.2585

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.